# TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).

> **NCT00449644** · PHASE2 · COMPLETED · sponsor: **Janssen Infectious Diseases BVBA** · enrollment: 208 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** TMC207
- **DRUG:** Placebo
- **DRUG:** Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)

## Key facts

- **NCT ID:** NCT00449644
- **Lead sponsor:** Janssen Infectious Diseases BVBA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2010-03
- **Final completion:** 2012-10
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2014-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00449644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00449644, "TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00449644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*